Just after market close, Adaptive Biotechnologies (ADPT 5.97%) took the wraps off its second quarter. The following day, investors reacted to this by bidding the biotech company's stock up by almost 6%. That was far higher than the 0.7% lift of the S&P 500 index that day.
MRD for the win
The commercial-stage Adaptive booked $58.9 million in revenue for the period, a robust 36% improvement over the same quarter of 2024. Much of this growth was due to the company's efforts fighting minimal residual disease (MRD), a cancer disorder in which a relatively small number of cancer cells remain in the body -- and thus present a threat -- after medical treatment.
Image source: Getty Images.
Adaptive revealed that its MRD business was responsible for 85% of the quarter's revenue. Its take grew 42% year over year.
At the bottom of the profit and loss statement, Adaptive recorded a net loss of $25.6 million ($0.17 per share). This was much narrower than the more than $46 million deficit of 2024's Q2.
With those numbers, the company scored an easy twin beat on the consensus analyst estimates. Those folks were modeling only $49 million and change for revenue, and a significantly deeper net loss of $0.24 per share.
A key revenue stream should flow harder
On the back of that encouraging growth in the MRD sphere, Adaptive raised its guidance for both the revenue from that business and cash burn.
It now expects that MRD will bring in $190 million to $200 million across the entirety of 2025, up from its previous projection of $180 million to $190 million. It did not proffer any guidance for its other major revenue stream, immune medicine. As for cash burn, over the year, it should be $45 million to $55 million. The preceding forecast called for $50 million to $60 million.
